- Home
- CRBU vs CSHRW Comparison
CRBU vs CSHRW Comparison
Compare CRBU & CSHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBU | CSHRW |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Jersey |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 167.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBU | CSHRW |
|---|---|---|
| Price | $1.59 | $0.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 4.4K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.63 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $0.56 |
| 52 Week High | $3.53 | $1.15 |
Technical Indicators
Market Signals| Indicator | CRBU | CSHRW |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 41.67 |
| Support Level | $1.39 | $0.73 |
| Resistance Level | $1.73 | $0.88 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.94 | 50.56 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.